Stifel analyst James Condulis resumed coverage of Mirum Pharmaceuticals (MIRM) with a Buy rating and $89 price target The firm views Mirum as “unique” in rare disease biotech given that it is cash flow positive, has a high-growth commercial business, and a pipeline with “multiple credible” growth opportunities. Stifel is bullish on Livmarli’s growth prospects and has “strong conviction” in volixibat ahead of primary biliary cholangitis data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals: Strong Buy Rating Backed by Robust Growth Prospects in Rare Disease Market
- Buy Rating Affirmed for Mirum Pharmaceuticals Amid Strong Financial Performance and Growth Potential
- Mirum Pharmaceuticals Reports Strong Q2 Growth and Raises Guidance
- Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond James
- Mirum Pharmaceuticals price target raised to $81 from $79 at Citizens JMP